Brain activity as a candidate biomarker for personalised caffeine treatment

in premature neonates

Short title: Caffeine for preterm neonates: brain activity as a biomarker

Fatima Usman[1#], Coen S. Zandvoort[1#], Shellie Robinson[1], Mariska Peck[1], Maria M.

Cobo[1,2], Tricia Adjei[1], Luke Baxter[1], Ria Evans Fry[1], Annalisa G. V. Hauck[1], Richard

Rogers[3], Gabriela Schmidt Mellado[1], Alexandra Scrivens[1], Marianne van der Vaart[1],

Maarten De Vos[4,5], Eleri Adams[6], John van den Anker[1,7] and Caroline Hartley[1*]

1. Department of Paediatrics, University of Oxford, Oxford, UK

2. Universidad San Francisco de Quito USFQ, Colegio de Ciencias Biologicas y

Ambientales, Quito, Ecuador

3. Nuffield Division of Anaesthetics, John Radcliffe Hospital, Oxford University Hospitals

NHS Foundation Trust, Oxford, UK

4. Department of Electrical Engineering (ESAT), STADIUS Center for Dynamical

Systems, Signal Processing and Data Analytics, KU Leuven, Leuven, Belgium

5. Department of Development and Regeneration, University Hospitals Leuven, Child

Neurology, KU Leuven, Leuven, Belgium

6. Newborn Care Unit, John Radcliffe Hospital, Oxford University Hospitals NHS

Foundation Trust, Oxford, UK

7. Division of Clinical Pharmacology, Children's National Hospital, Washington DC, USA

# These authors contributed equally

* Corresponding author: Caroline Hartley, Department of Paediatrics, University of

Oxford, UK.

caroline.hartley@paediatrics.ox.ac.uk

Abstract

Background

Medication in hospitalised infants is often prescribed using a 'one-size-fits-all' approach due to lack of clinical biomarkers. Caffeine is one of the most frequently administered medicines in neonatology - prescribed for the management of apnoea of prematurity, to aid extubation and increasingly for conditions such as bronchopulmonary dysplasia. Caffeine guidelines for the management of apnoea of prematurity indicate use based on the age of the infant, but this does not account for individual variation in apnoea rate. Consequently, infants may risk caffeine undertreatment or adverse events due to over-exposure. Apnoea in preterm infants is related to nervous system immaturity, hence, as an essential first step to assess whether brain activity may be a useful biomarker for caffeine treatment, we tested the hypothesis that apnoea rate is related to brain activity.

Methods and Findings

In this single-centre prospective observational cohort study, we simultaneously recorded brain activity using electroencephalography (EEG) and respiration using impedance pneumography in 74 infants aged 31-36 weeks postmenstrual age (PMA) on 138 separate occasions. We demonstrate that apnoea rate in moderate/late preterm infants is dependent on brain age gap (defined as the difference between the infant's age assessed from their brain activity and their PMA). In contrast, apnoea rate is not correlated with PMA in this age range. In an exploratory sub-study, we provide initial evidence that when caffeine is discontinued, infants with immature brain activity have

more frequent apnoeas and desaturations compared with those with more mature brain

function.

Conclusions

These findings provide initial evidence to indicate that brain age gap (assessed

automatically using machine learning) is a candidate biomarker for personalised caffeine

treatment in preterm infants.

Introduction

Apnoea of prematurity (AOP) is a developmental respiratory disorder affecting more than half of the 15 million infants born prematurely each year worldwide (1,2). Apnoea is a breathing cessation of variable duration which can be life-threatening and may impact long-term neurodevelopmental outcomes (3,4), so it is essential to optimise treatment. AOP is a consequence of nervous system and pulmonary immaturity of preterm infants (5) and will usually resolve by late prematurity (6).

Caffeine is the primary pharmacological treatment for AOP, reducing apnoea rates, duration of ventilatory support and extubation failure, and improving neurodevelopmental outcomes (7). Clinical guidelines for the treatment and prevention of AOP indicate caffeine requirement based on gestational age or weight of an infant. For example, the World Health Organisation recommends that all infants born before 34 weeks' gestation are given caffeine (8). Similarly, the European Consensus Guidelines suggests to 'use caffeine routinely in infants <32 weeks of gestation' (9) and the UK's National Institute for Health and Care Excellence (NICE) guidelines state 'use caffeine citrate routinely in preterm babies born at or before 30 weeks, starting it as early as possible and ideally before 3 days of age' (10). Moreover, NICE guidelines also suggest to 'consider stopping caffeine citrate at 33 to 35 weeks' corrected gestational age if the baby is clinically stable.' Whilst this does take into account the stability of the baby, it nevertheless also relates to age, precluding stopping treatment before 33 weeks. Prescription based on age does not directly relate to the underlying cause of apnoea (i.e., immaturity of the brain and

pulmonary systems) (Figure 1). This may expose some infants to caffeine-related adverse

effects, such as tachycardia, reflux and feeding intolerance, or rarely seizures (11,12) if,

for example, they are born just before the cut-off age and receive caffeine unnecessarily.

Conversely, some infants born just after the cut-off age, who are relatively neurologically

immature, and who may benefit from treatment, may not receive it immediately. Moreover,

some infants discontinue treatment too early and experience substantial apnoeas

necessitating recommencement of treatment (13). An individualised approach is needed

(14) and can be achieved through identification of biomarkers for caffeine requirement.

Currently, no such biomarkers have been identified.

Given the direct link between brain development and apnoea, here we propose brain

activity, and more specifically, a metric derived from brain activity known as the brain age

gap, as a candidate biomarker (Figure 1). We define brain age gap as the difference

between an infant's 'brain age' and their postmenstrual age (PMA) (15,16). Thus, the

brain age gap is a marker of whether an individual's brain activity is more or less mature

relative to their PMA, with negative values of brain age gap indicating that their brain

activity is immature compared with their PMA and positive values indicating that their

brain activity is more mature than their PMA. Brain age can be assessed using

electroencephalography (EEG), combined with recently developed and validated

machine learning models, and uses features in the EEG compared with the model training

data to ascertain an infant's brain age (17–20). These models capitalise on the fact that

the EEG changes rapidly in preterm infants – the EEG of a very preterm infant is

characterised by discontinuous activity interspersed with high amplitude bursts. Brain

activity becomes increasingly continuous and lower in amplitude with increasing age (21).

Similarly, sensory-evoked responses change with PMA (22–24). Very immature brain

activity relative to PMA may be associated with poorer later life neurodevelopmental

outcomes (17,18), yet there will also be normal variation in brain age gap – just as older

children learn to walk and talk at different ages, brain developmental trajectories exhibit

individual variation modulated by factors such as genetics and the environment (25,26).

We postulate that this individual variation in brain age gap (i.e., individual variation in EEG

activity) will explain variation in apnoea rate and consequently could be used to guide

treatment with caffeine.

Figure 1. Schematic of study concept, design and main results. EEG: electroencephalography, IP:

impedance pneumography, PMA: postmenstrual age. Note that other factors, such as infection, can lead

to apnoea in premature infants; however, here we focus on the relationship between apnoea and brain

development.

There is limited evidence to date to suggest that brain activity in human preterm infants

is related to apnoea rate: Henderson-Smart and colleagues (27) demonstrated prolonged

auditory brainstem conduction times in infants with AOP. Moreover, we recently

demonstrated that cortical brain activity (most likely originating from cortical motor areas)

is involved in the regulation of breathing in infants and that infants with stronger 'coupling'

between cortical and respiratory activity had lower incidences of apnoea (28). In the

present study, we hypothesised that, in late preterm infants, apnoea rate is related to

brain age gap and that this relationship is stronger than the relationship between apnoea

rate and PMA. Indeed, demonstrating that there is a significant correlation between

apnoea rate and brain age gap, and that this is stronger than the relationship between

apnoea rate and PMA, is an essential first step to suggest that brain age gap may be a

useful biomarker for caffeine treatment; if this were not the case then treatment based on

an alternative biomarker would be a better approach. For this study, we focused on

moderate-to-late preterm infants from 31–36 weeks PMA to investigate whether the brain

age gap can be used to assess caffeine requirement. It is possible that some of even the

youngest infants in this age range will not need to start caffeine treatment and that brain

age gap could be used to guide this decision. Moreover, brain age gap may be a

candidate biomarker to indicate when to discontinue treatment in those who have

received it, which is an important step in their care, expedites discharge and could shift

the balance in an individual from adverse effects and towards benefit.

147
148
149 **Results and Discussion**
150

We included 74 infants on 138 separate occasions (demographic information is provided

in Table 1). We included preterm infants between 31 – 36 weeks PMA who were stable

and without any significant respiratory or central nervous system complications at the time

of the EEG recording (additional details in the Methods). EEG and vital signs were

recorded for one to two hours, with continued vital signs recording in some infants up to

the time of discharge (see Methods). Sensory-evoked (visual and tactile) and resting state

EEG were used to calculate the brain age gap by applying previously developed and

validated models (17,18). We used both sensory-evoked and resting state models to

improve accuracy by assessing these different (i.e. sensory-evoked and resting state)

aspects of functional brain age gap; results using each model independently are

presented in the supplementary material and demonstrate similar trends to those

presented in the main results (Figure S8).

167 **Table 1. Infant demographics.**

Factors	
Age	
Gestational age at birth (weeks)	31.0 (23.6-36.6)
Postmenstrual age at recording (weeks)	34.0 (31.0-36.9)
Postnatal age at recording (weeks)	3.6 (0.0-11.4)
Birthweight (g)	1,573 (630-4,525)
Sex	
Females	25 (33.8)
Males	49 (66.2)
Mode of delivery	
Normal vaginal delivery	13 (17.6)
Vaginal breech	2 (2.7)
Vaginal assisted (ventouse/forceps/kiwi)	4 (5.4)
Elective Caesarean section	8 (10.8)
Emergency Caesarean section	47 (63.5)
Apgar scores	
Apgar at 1 minute	6.9 (1-10)
Apgar at 5 minutes	8.9 (2-10)
Apgar at 10 minutes	9.6 (6-10)
Ethnicity	
White	26 (35.1)
Asian	5 (6.8)
Black	1 (1.4)
Mixed	6 (8.1)
Other	1 (1.4)
Information not recorded	35 (47.3)
Resuscitation at birth	
Yes	55 (74.3)
No	19 (25.7)
Respiratory distress syndrome	
Ongoing condition	47 (34.1)
Past treated	57 (41.3)
No	34 (24.6)
Persistent pulmonary hypertension	
Past treated	4 (2.9)
No	134 (97.1)

Patent ductus arteriosus

Ongoing condition	9 (6.5)
Past treated	7 (5.1)
No	122 (88.4)

Jaundice

Ongoing condition	6 (4.3)
Past treated	78 (56.5)
No	54 (39.1)

Infection

None	61 (44.2)
Suspected	17 (12.3)
Treated	60 (43.5)

Level of care

Intensive Therapy Unit	6 (4.3)
High Dependency Unit	65 (47.1)
Low Dependency Unit	59 (42.8)
Postnatal care	5 (3.6)
Information not recorded	3 (2.2)

Respiratory support

High flow therapy	35 (25.4)
Low flow therapy	14 (10.1)
Spontaneous ventilation	88 (63.8)
Information not recorded	1 (0.7)

Medications received on the day of EEG recording

Vitamins and minerals	112 (81.2)
Probiotics	59 (42.8)
Breastmilk fortifier	56 40.6)
Caffeine	71 (51.4)
Antibiotics	6 (4.3)
Gaviscon	6 (4.3)
Paracetamol	2 (1.4)
Budesonide	6 (4.3)
Nystatin	1 (0.7)
Diuretics	1 (0.7)
No medication	16 (11.6)

Reported values are mean (range) or number (%). All demographic details are computed for every recording except

ethnicity, need for resuscitation at birth, and gestational age (which are provided per infant). Antibiotics include:

benzylpenicillin, gentamicin, coamoxiclav, cefotaxime, chloramphenicol, and amoxicillin; vitamins and minerals include:

abidec, calcium, phosphate, vitamin D, folic acid, and iron; diuretics include: chlorothiazide and spironolactone.

Apnoea rate was not significantly associated with PMA in the age range studied (p:0.58;

β [95% CI]:-0.04 [-0.16; 0.09]; ρ:-0.0472; E_{point}:1.26; E_{CI}:1.00; Figure 2A). Whilst we would

expect that apnoea rate decreases with PMA when considering a wider age range (6),

this result demonstrates that apnoea rate is not strongly related to PMA in older preterm

infants, highlighting potential pitfalls of guidelines based on age. Consistent with our

hypothesis, apnoea rate was significantly related to brain age gap (p:0.024; β [95% CI]:-

0.22 [-0.41; -0.03]; ρ:-0.19; E_{point}:1.83; E_{CI}:1.22; Figure 2B, comparison of the relationship

between apnoea rate and brain age gap versus apnoea rate and PMA: p:0.12; one-tailed

bootstrapped 95% CI: [-0.2287, 1]). There was a clear relationship between brain age

gap and the distribution of prolonged inter-breath intervals, with immature brain activity

associated with longer inter-breath intervals (Figure 2C), suggesting the association

between apnoea rate and brain age gap holds irrespective of the exact definition of

apnoea used, which is variable within clinical practice (29). This relationship between

apnoea rate and brain age gap was also observed in the subgroup of infants receiving

caffeine at the time of study (Supplementary Figure S9), providing preliminary indications

of the potential value of brain age gap as a biomarker for caffeine requirement. In preterm

infants, the development of central chemoreceptors is immature, and there is a blunted

central nervous system response to hypercapnia (30). This immaturity of respiratory

centres, which we postulate is related to general immaturity of the brain as assessed

here, likely underlies these results. Moreover, these results may be related to immaturity

of the cortical control of respiration (28).

Interestingly, when considering the average respiratory rate (i.e., normal breathing

between apnoeas) we observed the opposite results - respiratory rate significantly

decreased with PMA (p:0.0001; β [95% CI]:-1.87 [-2.81; -0.93]; ρ:-0.3186; E_{point}:2.37; E_{CI}:

1.75; Figure 2D, F) and respiratory rate did not significantly relate to brain age gap (p:0.18;

β [95% CI]:1.17 [-0.54; 2.88]; ρ:0.1149; E_{point}:1.77; E_{CI}: 1.00; Figure 2E). After birth, critical

changes in lung and chest wall dynamics play a major role in developing breathing

mechanics (31). With advancing PMA, lung alveoli mature both functionally and

anatomically, improving lung-chest wall elasticity (32). We speculate that these changes

play a major role in driving decreases in respiratory rate with advancing PMA. The

contrasting results between apnoea and respiratory rate underlie the distinction between

normal breathing and apnoea and further highlight the importance of utilising brain age

gap as a biomarker for caffeine requirement in preterm infants.

Figure 2. Apnoea rate and caffeine requirement are related to brain age gap.

The relationship between apnoea rate (defined as a pause in breathing of at least 15 seconds) and (A) postmenstrual age (PMA), and (B) brain age gap. Brain age gap is computed relative to the infant's PMA, with negative values indicating that the brain activity is immature relative to PMA. Each dot indicates an individual test occasion (A-F, 74 infants were included on 138 test occasions). Black line is the mean fit of

the linear model (β_{slope}, p, ρ, E_{point}, and E_{CI} in the titles are the predictor's regression slope, and its significance, partial correlation coefficient, E-value point estimate, and E-value of the confidence interval, respectively). (C) The cumulative probability distribution of inter-breath intervals split according to brain age gap. The distribution is shown on a double logarithmic scale to emphasise the prolonged inter-breath intervals (i.e., apnoeas). (D, E) The relationship between respiratory rate and (D) PMA and (E) brain age gap. (F) The probability density distributions of inter-breath intervals shown according to the infant's PMA. (G) The relationship between age at which caffeine treatment is discontinued (dependent on clinical decision) compared to brain age gap in the subset of 27 infants where brain activity was recorded in the two weeks before caffeine was discontinued. (H, I) Exploratory hypothesis-generating study in the subset of infants where vital signs were recorded longitudinally. Infants were grouped according to whether their brain activity was immature or mature relative to their PMA before they discontinued caffeine treatment. Error bars indicate mean and standard deviation. (H) Apnoea rate (n = 11 infants) and (I) desaturation rate (n = 17 infants) were computed in the 7 days after treatment was stopped. Statistical models in panels A and B are adjusted for data length of impedance pneumograph (i.e. the signal used to assess apnoea rate) and infection; panels D, E and G are adjusted for infection (see Supplementary Results for discussion of statistical models and Supplementary Figures S10-S16).

Guidelines for discontinuing caffeine treatment are related to PMA, but there is variation in when treatment is stopped (33), depending on clinical discretion and guided by the infant's physiological stability. Given that apnoea rate is related to brain age gap, we hypothesised that the age at which infants stopped caffeine treatment would be related to their brain age gap. In a subset of 27 infants who had their EEG recorded shortly before discontinuing caffeine treatment, we found that the age at which infants stopped caffeine treatment was correlated with their brain age gap (p:0.14; β [95% CI]:-0.26 [-0.61; 0.09]; ρ:-0.2839; E_{point}:1.99; E_{CI}:1.00; Figure 2**Figure 2**G) with infants with immature brain activity discontinuing caffeine at older ages (the decision to stop treatment was made by the

clinical team who were unaware of the brain age gap or EEG of the infant; note all infants

stop caffeine whilst in neonatal care, however, for most infants we did not record their

EEG at the time at which they stopped caffeine treatment and so they were not included

in this subset analysis). However, despite this association, some infants with relatively

mature brain activity continued caffeine close to term-corrected age, and, *vice versa*,

some infants with immature brain activity discontinued treatment at a much younger age.

Using an infant's brain age gap will provide an objective metric to identify when to

discontinue treatment.

Finally, in an exploratory hypothesis-generating study in a subset of infants who had

longitudinal recordings of vital signs throughout their hospital stay (see Methods), we

investigated whether there was a relationship between brain age gap (recorded before

infants discontinued caffeine), and apnoea rate in the 7 days after they discontinued

caffeine treatment. Infants with more mature brain activity (defined as brain age gap >0)

had 60% fewer apnoeas and 42% fewer oxygen desaturations after they stopped caffeine

treatment compared with those infants with immature brain activity (brain age gap <0)

(Apnoea rate, n=11: infants with mature brain activity: 0.41±0.40 apnoeas/hour

[mean±SD]; infants with immature brain activity: 1.02±0.60; Figure 2H; Desaturations

n=17: infants with mature brain activity: 0.26±0.38 desaturations/hour; infants with

immature brain activity: 0.45±0.33; Figure 2I). As this exploratory study was limited in

sample size and conducted to determine if there was any preliminary evidence of a

relationship between brain age gap and apnoea rate after caffeine discontinuation, no

statistical analyses were performed. This exploratory study is also limited in that it was a

single-centre study comprising mainly Caucasian babies (Table 1). The study did not

follow a pre-registered protocol and only examined the subset of infants that had

longitudinal recordings at the time of stopping caffeine. These results should therefore be

replicated in a prospective study before definitive conclusions can be drawn.

Nevertheless, our findings provide promising initial evidence that physiological instability

after discontinuation of caffeine is related to brain age gap.

The results presented here demonstrate that apnoea rate is related to brain age gap, not

postmenstrual age, in infants from 31–36 weeks. We focused on this age range as this is

the age at which doctors will consider whether or not infants require caffeine treatment,

and unlike at younger ages, not all infants will experience apnoea. In infants of this age

who are experiencing apnoea and/or desaturations, it can be difficult to disentangle the

cause, which may be brain immaturity but also other factors such as infection or feeding

problems – for which caffeine is not the best course of treatment. We propose that brain

age gap (once further validated in other studies) could be used as an objective approach

to dissociate the underlying mechanism of apnoea and determine whether it is

appropriate to stop caffeine treatment. Future work should also assess whether EEG can

be used as a biomarker for caffeine treatment in younger infants – whilst all extremely

preterm infants are likely to need caffeine at birth, it is plausible that brain age gap may

be a useful biomarker to indicate the dose of caffeine an individual will require.

We identified a significant relationship between apnoea rate and brain age gap,

nevertheless, there was heterogeneity in responses. Within the statistical model, we

adjusted for data length and the presence of infection, and additionally mode of ventilation

(see Supplementary Results). We did not adjust for gestational age or postnatal age, as

in our sample this was highly colinear with PMA (see Supplementary Results). Future

work to investigate heterogeneity in responses is required. Finally, further work is needed

to translate the results presented here into a clinically usable tool: EEG is already used

in neonatal units, however, technology to incorporate brain age assessment within an

EEG device is needed. Additionally, a prospective study evaluating the relationship

between brain age and apnoea rate after stopping caffeine treatment is needed. This

study could be used to build a model to identify the optimal brain age at which to stop

caffeine treatment in premature infants, which could then be assessed in a randomised

controlled trial.

In summary, we demonstrate that apnoea rate is related to brain age gap, not PMA, in

infants from 31-36 weeks PMA. We also provide promising initial evidence that brain age

gap is related to apnoea rate and oxygen desaturations in the week after caffeine is

stopped. Whilst the utilisation of brain age as a biomarker for caffeine requirement

requires additional validation, our current study provides a foundation for its use. There

is a need for personalised medicine in neonatology; this study demonstrates that brain

age gap is a key candidate biomarker for tailored caffeine treatment.

Methods

Study design and participants

This was a prospective cohort study conducted at the Newborn Care Unit of the John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK between 2019 and 2023. Clinically stable preterm infants aged between 31 and 36 weeks postmenstrual age (PMA) at the time of test occasion were eligible to be included in the study (from an age of 31 weeks and 0 days up to 36 weeks and 6 days). Infants were excluded if they had grade III or IV intraventricular haemorrhage, hypoxic ischaemic encephalopathy, congenital malformations, were on mechanical ventilation, receiving opioid analgesics at the time of study, or if there was a history of maternal substance misuse during pregnancy. These conditions are known to impact brain activity and may interfere with the interpretation of the EEG by acting as confounders. Previous studies on brain age models utilised similar inclusion and exclusion criteria (17,18).

The study was approved by the National Research Ethics Service (references: 19/LO/1085, 12/SC/0447). Eligible families were given verbal and written information about the study, and written parental consent was signed before inclusion in the study. The study conformed to the standards set by the Declaration of Helsinki and Good Clinical Practice.

An initial total of 76 infants were studied on 141 separate test occasions; 53 infants were included in one to three test occasions, 23 infants took part in the ongoing *Breathing and*

Brain Development study (34) where their EEG is recorded approximately once a week

and their vital signs recorded continuously whilst on the Newborn Care Unit (included on

average on 3±1 [mean ± SD] occasions). During each test occasion (which aimed to last

~2 hours), simultaneous electroencephalography (EEG) and vital signs (respiration, heart

rate and oxygen saturation) were recorded. Three test occasions were excluded due to

very short recordings of inter-breath intervals (see 'computing respiratory and apnoea

rate'), leaving a total of 74 infants studied on 138 test occasions included in the analysis.

336
Data acquisition
Vital signs recordings

Each infant had continuous vital signs monitoring as the standard of care. Vital signs were

monitored using Phillips IntelliVue MX800 or MX750 monitors and data were continuously

downloaded from the vital signs monitor using an electronic data capture software

(iXtrend, ixitos, Germany). For infants in the *Breathing and Brain Development* study, vital

signs were downloaded continuously throughout the infant's hospital stay; the recordings

from the day of the EEG test occasion are included in the main analysis (i.e., up to 24

hours of recording). For other infants, vital signs were recorded during EEG data

acquisition for an average of 1.5 hours (median, range: 0.4-3.3 hours).

Heart rate, oxygen saturation and respiratory rate (calculated by the monitor) were

downloaded onto the laptop at a sampling rate of 0.97 Hz; the electrocardiograph (ECG,

to measure heart rate) at 250 Hz and recorded with three electrodes placed on the infant's

chest; the impedance pneumography (IP, to measure respiration) at 62.5 Hz and

recorded from the chest electrodes, and the photoplethysmography (PPG, to measure

oxygen saturation and pulse) at 125 Hz from a probe placed on the infant's foot or hand.

EEG recordings

EEG was recorded from DC to 400 Hz using a SynAmps RT 64-channel headbox and

amplifiers and CURRYscan7 neuroimaging suite (Compumedics Neuroscan) at a

sampling rate of 2 kHz. Eight electrodes were placed at Cz, CPz, C3, C4, Oz, FCz, T3,

and T4, according to the modified international 10-20 system. The ground electrode was

placed at FPz and the reference electrode at Fz. Infant scalp preparation was done with

NuPrep gel (D.O. Weaver and Co., Aurora, USA) to achieve impedances of 5-10 kΩ. A

conductive paste (Elefix EEG paste, Nihon Kohden, Tokyo, Japan) was used to attach

disposable Ag/AgCl cup EEG electrodes (Ambu Neuroline, Ballerup, Denmark) to the

infant's scalp. At the beginning of each recording, approximately 10 background

annotations were time-locked on the EEG and vital signs recordings by manually pushing

a button connected to a bespoke triggering device (the PiNe box) (35) which

simultaneously annotates the EEG and vital signs recordings. This enabled

synchronisation of the vital signs and EEG recordings. Background annotations were

performed by a researcher during a period when the infant was quietly resting in their

cot/incubator. Resting-state EEG was recorded for an average of 1.7 ± 0.7 hours (mean

± SD). No clinical records on the normality of the EEG were available.

Tactile and visual stimuli

A tendon hammer was used to lightly tap the infant's foot to elicit touch responses. At

least 10 gentle touch stimuli, with an inter-stimulus interval of approximately 10 seconds

(longer if the infant was unsettled) were applied. The tendon hammer was modified with

a built-in force transducer (Brüel & Kjær, Denmark) that sends a trigger pulse at the point

of stimulation (36). For visual-evoked responses, the stimulus was a flash of light

presented using a Lifelines Photic Stimulator (intensity level 4, approximately 514

lumens). The Photic Stimulator was placed approximately 30 cm away from the infants,

in line with their direct field of vision and a train of 10 light flashes was delivered at least

10 seconds apart. The tactile and visual stimuli (order pseudo-randomised) were

performed either at the start or end of the EEG recording. The stimuli were annotated

simultaneously on the EEG and vital signs recordings using our custom-made time-

locking device (the PiNe box) (35).

Recording of infant demographics and clinical details

Relevant demographic and clinical information were obtained from the medical notes of

each infant and updated at each test occasion where relevant. These included the infant's

age at birth and sex, and at the time of the test occasion, the postmenstrual age, current

mode of ventilation and presence of infection. Infection was defined based on the

neonatal guidelines for infection treatment at the John Radcliffe Hospital as either an

elevated C-reactive protein of >10mg/L, abnormal white blood cell count (>20 x 10^9/L or

<5 x 10^9/L), a positive blood culture; or a symptomatic infant with predisposing factors for

sepsis receiving antibiotics at the time of EEG recording.

Data analysis

All analyses were performed in MATLAB (ver. 2022b; MathWorks Inc., Natick, USA). In

brief, we first computed respiratory and apnoea rates from the impedance pneumography

(IP) signals, and brain age gap from 20 minutes of resting state EEG activity and sensory-

evoked (visual and tactile) potentials. Next, we constructed linear (mixed-effects) models

to test if the respiratory outcomes – respiratory and apnoea rates – were associated with

either PMA or brain age gap. We also explored whether the PMA at which caffeine

treatment is discontinued relates to brain age gap. In a final exploratory analysis to

explore whether the brain age gap could be utilised as a predictive biomarker for stopping

caffeine treatment, we investigated whether the rate of episodes of physiological

instabilities (apnoea and oxygen desaturation rate) in the week after caffeine was stopped

is related to brain age gap. Each of these analysis steps are outlined in more detail below.

Computing respiratory and apnoea rate

To obtain respiratory and apnoea rates, IP signals were processed using an algorithm

validated for the identification of inter-breath intervals and apnoeas in infants (37). Briefly,

the algorithm first filters the signal to reduce the noise introduced by movements and

cardiac activity. An adaptive amplitude threshold (set at 0.4 times the standard deviation

of the signal over the preceding 15 breaths) is used to identify individual breaths. Finally,

a support vector machine algorithm was applied to all potential episodes of apnoea

(defined as inter-breath intervals longer than 15 seconds) to remove periods of low

amplitude erroneously identified as apnoeas due to noise or shallow breathing. This

model was trained and validated on IP signals acquired during a clinical trial (38). The

data from the clinical trial was completely independent from our current data sample. Long

inter-breath intervals (IBI) marked as noise/shallow breathing were discarded from further

analysis. We then computed respiratory and apnoea rates estimated from all available

IBIs on the day of the EEG recording, which was 8.5 ± 8.7 hours (mean ± SD over

recordings). We computed respiratory rates (expressed in times per minute) and apnoea

rates (in times per hour) estimated from all available IBIs on the day of the EEG recording.

We excluded three recordings which had fewer than 100 IBIs available. Apnoea rate was

calculated as the number of apnoeas (IBIs greater than 15 seconds) per hour. Respiratory

rate was computed as the median number of breaths per minute (i.e., 60 divided by the

median IBI of the recording).

Estimating brain age gap from EEG activity

To obtain the brain age gap, we first computed brain age using two brain age models

(17,18). These two models estimate the functional maturation of the brain using resting

state (18) and sensory-evoked EEG activity (17), respectively. These models aim to

capture different developmental aspects. The resting state model is an index for the

maturation of ongoing brain activity and the sensory-evoked model for the maturation of

sensory pathways (Supplementary Figure S1). Whilst both models use features extracted

from different neural systems, all features change in an age-related manner. Both are

machine learning models which are trained to estimate the age of the infant from the EEG

activity, with the aim of such models being to identify infants who deviate from normal

neurodevelopment. Thus, brain age is correlated with PMA, and large differences

between PMA and brain age may be indicative of abnormal outcome (17,18). Brain age

gap was defined as the mean brain age of the two models minus PMA (note, brain age

gap has also been referred to in the literature as the brain age delta). Figure S2 compares

brain age and respiration/apnoea rate.

Before estimating the brain age gap, EEG data were first pre-processed using the

Brainstorm (version 3) (39) and EEGLAB (version 2022.1) (40) toolboxes. EEG time

series were filtered with pass-band edges at 0.1 and 30 Hz by consecutively high-pass

(Hamming windowed-sinc FIR filter with a cut-off frequency at 0.05 Hz) and low-pass

filtering the signals (Hamming windowed-sinc FIR filter with a cut-off frequency at 33.75

Hz).

To calculate the infant's brain age from their sensory-evoked responses (visual and

tactile), we used the model developed by Zandvoort and colleagues (2024) (17). Briefly,

this model capitalises on the PMA-related changes in the morphology of sensory-evoked

potentials during the preterm period. The sensory-evoked data were first epoched from -

0.5 to 1.0 seconds around the stimulus onsets for channels Oz and Cz. Epochs were

baseline normalised by subtracting the mean amplitude of the time window between -0.5

and 0 seconds. Epochs were then visually inspected, and those with excessive

amplitudes or artefacts were excluded (an average of 10% of epochs were excluded).

Individual test occasions with fewer than five epochs of sensory-evoked data remaining

after artefact rejection were excluded from sensory-evoked brain age estimation (9 out of

138 recordings), and brain age was estimated using the resting state model alone for

these recordings. Visual and tactile evoked potentials were fitted to neurodynamic

response functions based on the characteristic waveforms of the evoked stimulus

responses (17) (Figures S3-S4 show the average evoked potentials). Zandvoort et al.

(2024) extracted these characteristic waveforms using principal component analysis. The

visual and tactile responses at channels Oz and Cz, respectively, can be captured by four

visual and two tactile neurodynamic response functions (17). Before fitting, evoked

responses were Woody filtered to the neurodynamic response functions to improve their

temporal alignment, allowing for individual infant differences in the latency of the evoked

response (maximum jitter: 50 ms; number of iterations: 1) (41). Neurodynamic response

functions were then fitted to the individual's evoked responses using a linear regression.

The regression's slope indicates the magnitude of the evoked response. The slopes were

obtained for the six neurodynamic response functions and forwarded as input for the

sensory brain-age model, which consisted of a support vector regression with a linear

kernel function using MATLAB's fitrsvm function (version 2022b; MathWorks). The output

of the model is the predicted sensory brain age for the infant (for further details, see

Zandvoort et al., 2024 (17)). The mean absolute error for data presented in this study is

comparable to the data presented in the original paper (Supplementary Figure S5).

To calculate the infants' resting state brain age, we used the model developed by Ansari

and colleagues (2024) (18). Data were first downsampled to 64 Hz, and the first 20

minutes of every recording was selected for analysis as this should warrant reliable brain

age estimates (18). EEG recordings were started when the infant was settled in their

cot/incubator and no overt artefacts were present (data length: 105 ± 41 minutes [31,

193]; mean ± standard deviation [range]). Since our studies comprised resting-state and

stimulus-evoked recordings, we selected a 20-minute window in which no visual or tactile

stimuli were applied. This enabled us to standardise the recording length used for analysis

across infants. However, in line with Ansari et al. (2024), we show that brain age

predictions estimated over 20 minutes are comparable to predictions from the full

recordings (Figure S6A) and that using the full recording to estimate the brain age does

not alter the relationship between apnoea rate and brain age gap (Figure S6B). For one

recording, the total data duration was less than 20 minutes, meaning that we did not have

sufficient data to calculate a reliable resting state brain age. For this recording, we only

used the brain-age estimate of the sensory model. For all recordings, the bipolar

derivative between channels C3 and C4 was used for brain age estimation. The data

were input into the deep neural network, and the output of the model was the predicted

resting state brain age for the recording (for further details, see Ansari et al. 2024 (18)).

Briefly, this algorithm segments the data into 30-second epochs and estimates a brain

age for each of them for ten iterations (the model consisted of a 10-learner ensemble

method). To obtain a single brain age value, the median over all ten ensembles was taken

for every 30-second epoch, after which a median over all 30-second epochs resulted in

a single value. To validate the output, Ansari et al. (2024) also used an independent test

set and found a MAE of 1.03 weeks for the held-out dataset. Their model also yielded a

significantly lower MAE than a null model estimating the mean PMA of the dataset. Model

applications revealed mean absolute errors of 1.22 and 0.77 weeks for the sensory-

evoked and resting state models within the data studied here. These accuracies are

comparable to those reported in the original studies which were 1.41 and 0.79 weeks.

Moreover, for model training, Ansari et al. (2024) used data of infants with normal

neurodevelopmental outcome at 24-month follow-up (assessed with BSID-II). Their

model was validated on EEG data that were labelled as normal by a neurophysiologist.

Neither brain age models take into account the different sleep states. Whilst it is known

that sleep states alter EEG activity in infants (21), derived brain ages are marginally

affected by it according to earlier versions of the model (42).

We obtained a single brain age prediction by averaging the brain ages of both models.

Since the models may estimate brain age with systematic prediction errors relative to

PMA (16), we corrected for this by first fitting a linear model between the combined brain

age and PMA. We next predicted PMA from this model and defined the model bias as the

difference between the PMA and predicted PMA (meaning that brain age gap and PMA

are completely uncorrelated). Next, brain age was corrected by subtracting the bias from

the brain age (relative to PMA). This age-bias correction is a standard approach in the

brain age field (16,43). This also ensured that the brain age gap and PMA were

uncorrelated. However, without this bias correction, similar results were obtained

(Supplementary Figure S7).

Probability density functions for the inter-breath intervals

To study how the IBI dynamics changed with PMA and brain age gap, we created

probability density functions. To do so, we first created a frequency distribution from the

IBIs of each recording a resolution of 0.1 seconds. IBIs longer than 50 seconds were

removed from further analysis. Distributions of each recording were normalised so that

the area under the curve was equal to 1, allowing for inter-recording comparisons. We

next transformed these recording-specific probability density functions into functions

specific for a PMA/brain age gap. For this, a weight of 1 or lower was assigned to the

recording-specific probabilities, depending on the infant's PMA/brain age gap. Weights

were determined using a Gaussian window with a full width at half maximum of 13 days.

Weightings for differences of more than 14 days were set to 0. Distributions that were

specific to a certain PMA/brain age gap were computed as the weighted median of all

distributions together with their weights (44). We created probability density functions

between 31 and 36 weeks for the PMA and between -3 and 3 weeks for the brain age

gap.

Statistical analysis

To compare PMA and brain age gap with apnoea rate and respiration rate, we used linear

mixed-effects models (computing four models for each of apnoea rate and respiration rate

against PMA and brain age gap separately). Previous literature suggested that

experiencing apnoeas is inversely associated with gestational age at birth (27,30). The

course of this relationship is, however, unknown which is why we used linear models as

a starting point. Nevertheless, we tested the assumption of linearity (see Supplementary

material and Table S1) using the mfp package in R. Moreover, it is not known how apnoea

rate varies with brain age gap. A linear fit was appropriate for the data collected here so

as not to overfit the data; however, whether a linear association underlies the brain age

gap/apnoea relationship needs to be studied in future research. Data length of the IBI

recordings and infection ('no', 'suspected', or 'treated') were included as fixed factors and

infant was included as a random factor (to account for the repeated test occasions in the

same infant). Data length and infection were included as confounding factors. P-values

(for the slopes of PMA and brain age gap) and partial correlation coefficients and their

95% confidence intervals are reported from these models. The normality assumption was

verified with Q-Q plots. Further discussion of the fixed factors to include within the model,

and assessment of the results with alternative factors is included in the Supplementary

Material. To test for the robustness of the associations and to estimate the strength of

unmeasured confounders, we report E-values (45). Reporting E-values is the most

common method for observational medical studies (46). We provide E-values for the

observed association estimate and the confidence interval limit that is closest to null,

computed via https://www.evalue-calculator.com. For visualisation, (we used the

plotAdjustedResponse function in MATLAB to adjust for the fixed factors (calculating a

separate model without the random effect of infant to do so). Regression lines are

visualised by calculating the line-of-best-fit on the adjusted data.

To test if apnoea rate is better associated with brain age gap than PMA, we first

bootstrapped the partial correlation coefficient between apnoea rate and PMA using

10,000 repetitions. This allowed us to generate a 95% confidence interval for the

association between apnoea rate and PMA. To test if the partial correlation coefficient

between brain age gap and apnoea rate lies outside this interval, the significance value

was defined as the number of bootstrapped partial correlation coefficients that were equal

to or lower than the true partial correlation coefficient between brain age gap and apnoea

rate. Significance was tested one-tailed with an alpha level of 0.05.

For the association between brain age gap and age at caffeine termination, we focused

on a subset of 27 infants who had their brain age gap assessed within two weeks before

they stopped caffeine treatment (note that infants were all receiving caffeine during the

EEG recording). Note, the age at which caffeine was stopped was dependent on clinical

decision and independent of the research study. A linear regression was used with

infection status as a fixed factor (data length was not included as a fixed factor as all EEG

was analysed using a fixed data length, and respiratory data was not analysed for this

question). For visualisation, we used the plotAdjustedResponse function adjusting for the

fixed effect of infection status only and the regression line was calculated as the line-of-

best-fit of the adjusted data.

In the exploratory analysis, we compared brain age gap before infants stopped caffeine

treatment with apnoea rate and oxygen desaturation rate in the week after they stopped

caffeine treatment. In a subset of infants (n=17) with longitudinal recordings of vital signs

throughout their hospital stay, infants were divided into two groups depending on their

brain age gap – either mature if their brain age gap >0 weeks or immature if their brain

age gap <0 weeks. The brain age gap was calculated from a single EEG recording taken

in the two weeks before they stopped caffeine. Apnoeas and desaturations were identified

from the recordings in the 7 days after caffeine was stopped (the age at which caffeine

was stopped was dependent on clinical decision and independent of the research study).

Desaturation events were defined as 10-second periods in which the oxygen saturation

was less than 80% (38). The type of vital signs monitoring was dependent on clinical

decision, and so 6 out of 17 infants did not have their IP signal measured during this week

(only oxygen saturation and pulse were monitored using a PPG), and they were

consequently excluded from the apnoea rate analysis. Due to the limited sample sizes,

and as this was an exploratory hypothesis-generating study, we did not apply any

statistics and reported outcomes as mean and standard deviation.

Acknowledgements

This work is funded by the Wellcome Trust and Royal Society through a Sir Henry Dale Fellowship awarded to CH (grant number: 213486/Z/18/Z). FU is funded by the Commonwealth Scholarship Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank the babies and their parents who took part in this research.

References

1. Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023;402(10409):1261–71.

2. Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary proceedings from the apnea-of-prematurity group. Pediatrics. 2006;117(3):S47–51.

3. Pillekamp F, Hermann C, Keller T, Von Gontard A, Kribs A, Roth B. Factors influencing apnea and bradycardia of prematurity - Implications for neurodevelopment. Neonatology. 2007;91(3):155–61.

4. Janvier A, Khairy M, Kokkotis A, Cormier C, Messmer D, Barrington KJ. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol. 2004;24:763–8.

5. Williamson M, Poorun R, Hartley C. Apnoea of prematurity and neurodevelopmental outcomes: Current understanding and future prospects for research. Front Pediatr. 2021;9:1–9.

6. Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J. 1981;17(4):273–6.

7. Moschino L, Zivanovic S, Hartley C, Trevisanuto D, Baraldi E, Roehr CC. Caffeine in preterm infants: where are we in 2020? ERJ Open Res. 2020;6(1):1–19.

8. Care of Preterm or Low Birthweight Infants Group. New World Health Organization recommendations for care of preterm or low birth weight infants: Health policy. eClinicalMedicine. 2023;63:1–13.

9.   Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E,

et al. European consensus guidelines on the management of respiratory distress

syndrome: 2022 update. Neonatology. 2023;120(1):3–23.

10.   National Institute for Health and Care Excellence. Specialist neonatal respiratory

care for babies born preterm. NICE; 2019 [cited 2025 Jun 10]. Available from:

https://www.nice.org.uk/guidance/ng124/chapter/Recommendations#managing-

respiratory-disorders

11.   Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Caffeine therapy in preterm infants.

World J Clin Pediatr. 2015;4(4):81–93.

12.   Vesoulis ZA, McPherson C, Neil JJ, Mathur AM, Inder TE. Early high-dose caffeine

increases seizure burden in extremely preterm neonates: A preliminary study. J

Caffeine Res. 2016;6(3):101.

13.   Haddad W, Sajous C, Hummel P, Guo R. Discontinuing caffeine in preterm infants

at 33-35 weeks corrected gestational age: Failure rate and predictive factors. J

Neonatal Perinatal Med. 2015;8(1):41–5.

14.   Schmidt B. Caffeine for apnea of prematurity: Too much or too little of a good thing.

J Pediatr. 2023;259:1–5.

15.   Anatürk M, Kaufmann T, Cole JH, Suri S, Griffanti L, Zsoldos E, et al. Prediction of

brain age and cognitive age: Quantifying brain and cognitive maintenance in aging.

Hum Brain Mapp. 2020;42:1626–40.

16.   Smith SM, Vidaurre D, Alfaro-Almagro F, Nichols TE, Miller KL. Estimation of brain

age delta from brain imaging. Neuroimage. 2019;200:528–39.

17.   Zandvoort CS, van der Vaart M, Robinson S, Usman F, Schmidt Mellado G, Evans

663   Fry R, et al. Sensory event-related potential morphology predicts age in premature

664   infants. Clin Neurophysiol. 2024;157:61–72.

665   18.   Ansari A, Pillay K, Arasteh E, Dereymaeker A, Schmidt Mellado G, Jansen K, et al.

666   Resting state electroencephalographic brain activity in neonates can predict age

667   and is indicative of neurodevelopmental outcome. Clin Neurophysiol.

668   2024;163:226–35.

669   19.   Stevenson N, Oberdorfer L, Tataranno M, Breakspear M, Colditz P, de Vries L, et

670   al. Automated cot-side tracking of functional brain age in preterm infants. Ann Clin

671   Transl Neurol. 2020 Jun 1;7(6):891–902.

672   20.   Stevenson NJ, Tataranno ML, Kaminska A, Pavlidis E, Clancy RR, Griesmaier E,

673   et al. Reliability and accuracy of EEG interpretation for estimating age in preterm

674   infants. Ann Clin Transl Neurol. 2020;7(9):1564–73.

675   21.   André M, Lamblin M, D'Allest A, Curzi-Dascalova L, Mousalli-Salefarnque F,

676   Nguyen The Tich S, et al. Electroencephalography in premature and full-term

677   infants. Developmental features and glossary. Clin Neurophysiol. 2010;40:59–124.

678   22.   Van Der Vaart M, Hartley C, Baxter L, Mellado GS, Andritsou F, Cobo MM, et al.

679   Premature infants display discriminable behavioral, physiological, and brain

680   responses to noxious and nonnoxious stimuli. Cereb Cortex. 2022;32:3799–815.

681   23.   Colonnese MT, Kaminska A, Minlebaev M, Milh M, Bloem B, Lescure S, et al. A

682   conserved switch in sensory processing prepares developing neocortex for vision.

683   Neuron. 2010;67(3):480–98.

24.   Chipaux M, Colonnese MT, Mauguen A, Fellous L, Mokhtari M, Lezcano O, et al.

Auditory stimuli mimicking ambient sounds drive temporal "delta-brushes" in

premature infants. PLoS One. 2013;8(11):e79028.

25.   Molloy MF, Saygin ZM. Individual variability in functional organization of the

neonatal brain. Neuroimage. 2022;253:119101.

26.   Lenroot RK, Giedd JN. The changing impact of genes and environment on brain

development during childhood and adolescence: Initial findings from a

neuroimaging study of pediatric twins. Dev Psychopathol. 2008;20(4):1161–75.

27.   Henderson-Smart DJ, Pettigrew AG, Campbell DJ. Clinical apnea and brain-stem

neural function in preterm infants. N Engl J Med. 1983;308:353–7.

28.   Zandvoort CS, Usman F, Robinson S, Fatunla O, Pattinson KT, Farmer SF, et al.

Cortical motor activity modulates respiration and reduces apnoea in neonates. Elife.

2025;14:RP107081.

29.   Elder DE, Campbell AJ, Galletly D. Current definitions for neonatal apnoea: Are

they evidence based? J Paediatr Child Health. 2013;49(9):E388–96.

30.   Erickson G, Dobson NR, Hunt CE. Immature control of breathing and apnea of

prematurity: the known and unknown. J Perinatol. 2021;41:2111–23.

31.   Heldt GP. Development of stability of the respiratory system in preterm infants. J

Appl Physiol. 1988;65(1):441–4.

32.   Trachsel D, Erb TO, Hammer J, von Ungern-Sternberg BS. Developmental

respiratory physiology. Paediatr Anaesth. 2022 Feb 1;32(2):108–17.

33.   Ji D, Smith PB, Clark RH, Zimmerman KO, Laughon M, Ku L, et al. Wide variation

in caffeine discontinuation timing in premature infants. J Perinatol. 2020;40:288–

93.

34.   Hartley C. Breathing and brain development, version 1.0 - NHS Health Research

Authority. 2024 [cited 2024 Mar 18]. Available from:

https://www.hra.nhs.uk/planning-and-improving-research/application-

summaries/research-summaries/breathing-and-brain-development-version-10/

35.   Worley A, Pillay K, Cobo MM, Schmidt Mellado G, Van Der Vaart M, Bhatt Id A, et

al. The PiNe box: Development and validation of an electronic device to time-lock

multimodal responses to sensory stimuli in hospitalised infants. PLoS One.

2023;18(7):e0288488.

36.   Worley A, Fabrizi L, Boyd S, Slater R. Multi-modal pain measurements in infants. J

Neurosci Methods. 2012;205(2):252–7.

37.   Adjei T, Purdy R, Jorge J, Adams E, Buckle M, Evans Fry R, et al. New method to

measure interbreath intervals in infants for the assessment of apnoea and

respiration. BMJ Open Respir Res. 2021;8(1):1–9.

38.   Hartley C, Moultrie F, Hoskin A, Green G, Monk V, Bell JL, et al. Analgesic efficacy

and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study:

randomised placebo-controlled trial. Lancet. 2018;392(10164):2595–605.

39.   Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM. Brainstorm: A user-friendly

application for MEG/EEG analysis. Comput Intell Neurosci. 2011;879716:1–13.

40.   Delorme A, Makeig S. EEGLAB: An open source toolbox for analysis of single-trial

EEG dynamics including independent component analysis. J Neurosci Methods.

2004;134:9–21.

41. Woody CD. Characterization of an adaptive filter for the analysis of variable latency
neuroelectric signals. Med Biol Eng. 1967;5(6):539–54.

42. Pillay K, Dereymaeker A, Jansen K, Naulaers G, De Vos M. Applying a data-driven
approach to quantify EEG maturational deviations in preterms with normal and
abnormal neurodevelopmental outcomes. Sci reports. 2020;10(7288):1–14.

43. Kalc P, Dahnke R, Hoffstaedter F, Gaser C, Alzheimer's Disease Neuroimaging
Initiative. BrainAGE: Revisited and reframed machine learning workflow. Hum Brain
Mapp. 2024;45:1–11.

44. Haase S. MATLAB Central File Exchange. 2024 [cited 2024 Jun 3]. Weighted
median.   Available   from:
https://www.mathworks.com/matlabcentral/fileexchange/23077-weighted-median

45. Vanderweele TJ, Ding P. Sensitivity analysis in observational research: introducing
the E-value. Ann Intern Med. 2017;167:268–74.

46. Latour CD, Delgado M, Su IH, Wiener C, Acheampong CO, Poole C, et al. Use of
sensitivity analyses to assess uncontrolled confounding from unmeasured
variables in observational, active comparator pharmacoepidemiologic studies: a
systematic review. Am J Epidemiol. 2024;00:1–12.

Data and code availability

Example resting state data as well as processed data (including brain age gap, apnoea

rates and predictor variables for each individual) and the codes for the analysis are

available at: https://github.com/CoenZandvoort/Brain_maturity_respiration. The brain

age models can be found at: https://github.com/amirans65/brainagemodel and

https://gitlab.com/paediatric_neuroimaging/sensory-brain-age-model. The algorithm for

inter-breath interval detection is online at:

https://gitlab.com/paediatric_neuroimaging/identify_ibi_from_ip. Due to ethical

requirements, the raw data that support the findings of this study are available upon

request to the corresponding author (caroline.hartley@paediatrics.ox.ac.uk).

Supplementary Material: Brain activity as a candidate biomarker for personalised caffeine treatment in premature neonates

Fatima Usman[#], Coen S. Zandvoort[#], Shellie Robinson, Mariska Peck, Maria M. Cobo, Tricia Adjei, Luke Baxter, Ria Evans Fry, Annalisa G. V. Hauck, Richard Rogers, Gabriela Schmidt Mellado, Alexandra Scrivens, Marianne van der Vaart, Maarten De Vos, Eleri Adams, John van den Anker and Caroline Hartley

Supplementary Results

Regression models
This section contains some further details on the linear models used in the analysis. We considered a number of factors within the statistical analysis and expand on this further here.

Potential factors to include in the model were considered to be:
1. Data length of the impedance pneumography (IP) recording – the recording used to calculate apnoea rate and respiratory rate. Note that data length used in the EEG analysis was the same for all recordings and so was not considered as a factor.
2. Presence of infection
3. Current mode of ventilation
4. Gestational age at birth
5. Postnatal age

We discuss each of the factors in turn in the following.

1. Data length of IP signal. Data length varied substantially across studies due to the inclusion of two study designs – some infants were part of the *Breathing and Brain Development* study and so had up to 24 hours of data from the day of EEG recording, other infants were included for a shorter (approximately 1-2 hour) recording (see Methods). As apnoeas are a relatively rare event – occurring approximately once an hour – apnoea detection using short recordings is at risk of underestimating apnoea rate, and so, data length was included in the statistical model of apnoea rate. Respiratory rate (the mean respiration during normal breathing) can be accurately estimated with short data lengths and so data length was not included in models of respiratory rate.

2. Presence of infection was considered a confound variable and so was included in the main statistical model. Given that the presence of infection may increase apnoea rate, we further validated the main results as presented in Figure 2, by also considering the subset of infants who did not have infection at the time of study (Figure S10). In line with our main results, apnoea rate was significantly related to brain age gap in this subset (*p*: 0.02; β [95% CI]: -0.21 [-0.38; -0.03]; ρ: -0.21) but not postmenstrual age (PMA) (*p*: 0.19; β [95% CI]: -0.07 [-0.18; 0.04]; ρ: -0.12).

3. Mode of ventilation is related to PMA, with younger infants more likely to be receiving
high flow therapy and older infants more likely to be self-ventilating. All infants in this study
were receiving either high flow therapy, low flow therapy or self-ventilating at the time of
study. Apnoea rate and respiratory rate are also related to mode of ventilation and so
mode of ventilation may act as a mediator variable (rather than a confound variable). We
therefore chose not to include it in the main statistical analysis but have also assessed
the results with inclusion of this factor (Figure S11). Apnoea rate reveals a strong trend
with brain age gap, but not with PMA (brain age gap: p: 0.06; β [95% CI]: -0.18 [-0.37;
0.01]; ρ: -0.16; PMA: p: 0.67; β [95% CI]: -0.03 [-0.15; 0.10]; ρ: -0.04). Moreover, to further
validate the main results, we conducted a subgroup analysis with self-ventilating infants
(Figure S). This demonstrated a correlation in the same direction between apnoea rate
and brain age gap (p: 0.10; β [95% CI]: -0.20 [-0.44; 0.04]; ρ: -0.17; PMA: p: 0.51; β [95%
CI]: 0.04 [-0.09; 0.18]; ρ: -0.07) but due to the lower sample size in this group (n=57 infants
on 89 occasions) we were likely underpowered to demonstrate a significant effect.
820
821   We considered gestational age (age in weeks at birth) and postnatal age (expressed as
822   age in weeks after birth). Both are highly correlated with PMA (age in weeks at the time
823   of study, which is the sum of gestational age and postnatal age) (Figure S13) and we,
824   hence, did not add these to the model due to issues with collinearity.
825
826
Linearity of factors
We tested the assumption of linearity for the linear models (Figure 2A, B, D, E, and G)
using multivariable fractional polynomial models. These models determine whether
relationships are better modelled through non-linear relationships by finding the most
appropriate functional form for every continuous predictor. Using the mfp package in R,
we estimated these most appropriate forms and statistically tested them against the factor
being included as linear. We included the same factors as presented in the main text
(Figure 2A, B, D, E, and G; i.e., infection and data length when estimating apnoea rate
and infection for respiration rate). For all models, infant was added as random factor. The
p-values of Table S1 represents the difference in deviances between the fractional
polynomial and linear models. As indicated by this table, none of the p-values for any
model were statistically significant, confirming the linearity assumption.
839
840   Table S1. Statistical output of fractional polynomials relative to linear models

Main text figure	Predictor	Response	P-value
2A	Postmenstrual age	Apnoea rate	0.49
2B	Brain age gap	Apnoea rate	0.67
2D	Postmenstrual age	Respiration rate	0.50
2E	Brain age gap	Respiration rate	0.93
2G	Brain age gap	PMA at caffeine cessation	0.99

841
Exploratory hypothesis-generating findings
In the main text we identified a possible relationship between brain age gap and apnoea
rate in the week after caffeine treatment is discontinued, in an exploratory hypothesis-
generating study. For a power calculation for future studies, based on the apnoea rates

from our analyses, we obtained an effect size of 1.19 using these values in G*power 3.1,
and together with an α of 0.05 and power of 0.95, the required sample size is n = 34 for
both groups (i.e., 17 participants per group).
849

850
851 **Figure S1. Brain age gap estimates from the two brain age models (computed from the sensory-**
852 **evoked and resting state EEG activity).** Brain age gap is computed relative to the age of the infant, with
853 negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values
854 indicating that the brain activity is more mature relative to the infant's PMA. Each dot indicates an individual
855 test occasion.
856
857

858
Figure S2. Respiration and apnoea rate compared with brain age. Brain age associations with **A)**
respiration rate and **B)** apnoea rate. Brain age gap (as presented in the rest of the text) is defined as the
difference in brain age minus postmenstrual age (PMA) (i.e. brain age is PMA plus brain age gap). Each
dot indicates an individual test occasion (74 infants were studied on 138 test occasions). Black line is the
mean fit of the linear model. Regression models are adjusted for infection, data length of inter-breath
intervals, and postmenstrual age.
865
866

868   **Figure S3. Recording-specific evoked potentials for the visual stimuli.** Average (across all visual
869   stimuli) evoked response for each individual recording, with the infants age and brain age gap indicated in
870   the title of each subplot. Recordings are ordered according to increasing postmenstrual age (PMA).
871   Stimulus was applied at Time = 0 sec. BAG: brain age gap; w: weeks.

Figure S4. Recording-specific evoked potentials for the tactile stimuli. Average (across all visual stimuli) evoked response for each individual recording, with the infants age and brain age gap indicated in the title of each subplot. Recordings are ordered according to increasing postmenstrual age (PMA). Stimulus was applied at Time = 0 sec. BAG: brain age gap; w: weeks.

Figure S5. Validation of the sensory-evoked brain age model. The sensory-evoked model developed by Zandvoort et al. had an overlap with the data presented in this paper of 59 [out of 128] recordings from 48 babies. To check that this did not affect the results presented in the main text we investigated **A)** the relationship between brain age gap and apnoea rate excluding the sensory brain age estimates of babies that were part of the training set in Zandvoort et al. This showed similar results. Further, we validated the sensory-evoked model on the data that was not part of the original training set. **B-C**) Sensory brain age (gap) relationships with postmenstrual age for the data that was not included in the training set. The mean absolute error for this data was 1.22 weeks which is comparable to the mean absolute error of 1.41 weeks for the training dataset in the original paper.

889
Figure S6. Effects of data length on resting state brain ages. A) Resting state brain ages predicted by
20-minutes epochs against those estimated over full recordings. The 20-minute epochs were used in the
main results as this provided a consistent data length across all recordings and was the minimum data
length which can be reliably used by the model as identified by Ansari et al.[14] **B)** Apnoea rate association
with brain age gap when full recordings are used to estimate resting state brain age. The black line is the
mean fit of a linear mixed effects model. Brain age gap is computed relative to the age of the infant, with
negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values
indicating that the brain activity is more mature relative to the infant's PMA. For both panels, each dot
indicates an individual test occasion.
899
900

β_{slope}: -0.16; p: 0.07; ρ: -0.15

Figure S7. Effects of bias correction on resulting association between apnoea rate and brain age gap. Brain age gap is estimated from both resting state and sensory model. However, here we did not correct for deviations between brain age and PMA, which allowed for correlations between brain age gap and PMA. This still resulted in a significant relationship between brain age gap and apnoea rate. The black graph is the mean fit of a linear mixed effects model. Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to the infant's PMA. Each dot indicates an individual test occasion.

Figure S8. Apnoea rate against brain age gap using the brain ages from different models. Apnoea
rate associations with **A)** both models, **B)** resting state model, and **C)** sensory model. Brain age gap is
computed relative to the age of the infant, with negative values indicating that the brain activity is immature
relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to
the infant's PMA. Each dot indicates an individual test occasion. Black line is the mean fit of the linear
model. Regression models are adjusted for infection and data length of inter-breath intervals.

922

923
924
Figure S9. Apnoea rate against postmenstrual age and brain age gap for infants receiving caffeine
at the time of study. Apnoea rate associations with **A)** postmenstrual age (PMA) and **B)** brain age gap.
Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain
activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is
more mature relative to the infant's PMA. Each dot indicates an individual test occasion (40 infants were
studied on 71 test occasions). Black line is the mean fit of the linear model. Regression models are
adjusted for infection and data length of inter-breath intervals.

932
Figure S10. Apnoea rate against postmenstrual age and brain age gap for infants without infection
at the time of study. Apnoea rate associations with **A)** postmenstrual age (PMA) and **B)** brain age gap.
Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain
activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is more
mature relative to the infant's PMA. Each dot indicates an individual test occasion (69 infants were studied
on 121 test occasions). Black line is the mean fit of the linear model. Regression models are adjusted for
infection and data length of inter-breath intervals.
940

941
Figure S11. Apnoea rate against postmenstrual age and brain age gap with the linear regression
models adjusted for data length, suspected infection and mode of ventilation. Apnoea rate
associations with **A)** postmenstrual age (PMA) and **B)** brain age gap. Brain age gap is computed relative
to the age of the infant, with negative values indicating that the brain activity is immature relative to the
infant's PMA, and positive values indicating that the brain activity is more mature relative to the infant's
PMA. Each dot indicates an individual test occasion (74 infants were studied on 138 test occasions). Black
line is the mean fit of the linear model. Regression models are adjusted for infection, data length of inter-
breath intervals and mode of ventilation.

951
Figure S12. Apnoea rate against postmenstrual age and brain age gap for self-ventilating babies.
Apnoea rate associations with **A)** postmenstrual age (PMA) and **B)** brain age gap. Brain age gap is
computed relative to the age of the infant, with negative values indicating that the brain activity is immature
relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to
the infant's PMA. Each dot indicates an individual test occasion (57 infants were studied on 89 test
occasions). Black line is the mean fit of the linear model. Regression models are adjusted for infection and
data length of inter-breath intervals.

960
961 **Figure S13. Correlations between A) postmenstrual age and gestational age, and B) postmenstrual**
962 **age and postnatal age.**
963

Figure S14. Associations between brain age (gap) with postmenstrual age, gestational age and post-natal age. Brain age is estimated from both the resting state and sensory model. The black graph is the mean fit of a linear mixed effects model. Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to the infant's PMA. Each dot indicates an individual test occasion.

Figure S15. Associations between brain age (gap) with postmenstrual age, gestational age and post-natal age using the resting state model. Brain age is estimated from the resting state model. The black graph is the mean fit of a linear mixed effects model. Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to the infant's PMA. Each dot indicates an individual test occasion.

Figure S16. Associations between brain age (gap) with postmenstrual age, gestational age and post-natal age using the sensory-evoked activity. Brain age is estimated from the sensory model. The black graph is the mean fit of a linear mixed effects model. Brain age gap is computed relative to the age of the infant, with negative values indicating that the brain activity is immature relative to the infant's PMA, and positive values indicating that the brain activity is more mature relative to the infant's PMA. Each dot indicates an individual test occasion.